Avanos SVP granted options and RSUs

Avanos Medical senior vice president of operations Sigfrido Delgado received new equity compensation awards.

Rhea-AI Filing Summary

Avanos Medical senior vice president of operations Sigfrido Delgado received new equity compensation awards. He was granted 37,520 employee stock options with an exercise price of $13.69 per share, expiring on March 13, 2036, along with 15,886 time-based restricted share units.

The restricted share units are scheduled to vest in installments between March 13, 2027 and March 13, 2029, and each unit represents one share of common stock. Following these grants, Delgado directly holds 59,434 stock options and 60,005 shares of Avanos Medical common stock. These are compensation awards, not open-market purchases.

Insider Trade Summary

Grant/Award: 53,406 shares

Grant/Award 2 txns

Insider Delgado Sigfrido

Role SVP, Operations

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	37,520	$0.00	$0.00
Grant/Award	Common Stock	15,886	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 59,434 contracts (Direct); Common Stock — 60,005 shares (Direct)

Footnotes (2)

1. F1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.
2. F2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Key Figures

Stock options granted: 37,520 options Option exercise price: $13.69 per share Option expiration: March 13, 2036 +5 more

8 metrics

Stock options granted 37,520 options Employee Stock Option grant on March 13, 2026

Option exercise price $13.69 per share Exercise price for newly granted options

Option expiration March 13, 2036 Expiration date for new stock options

Restricted share units granted 15,886 RSUs Time-based restricted share unit award

Options held after grant 59,434 options Total stock options following transaction

Shares held after grant 60,005 shares Common stock directly owned after grant

RSU vesting schedule 2027 1/3 of award TRSUs vest one-third on March 13, 2027

RSU vesting schedule 2028–2029 1/3, 1/3 of award TRSUs vest one-third on March 13, 2028 and 2029

Key Terms

Employee Stock Option (right to buy), time-based restricted share units (TRSUs), 2021 Long Term Incentive Plan, economic equivalent of one share of Common Stock, +1 more

5 terms

Employee Stock Option (right to buy) financial

"security_title: "Employee Stock Option (right to buy)""

time-based restricted share units (TRSUs) financial

"Represents time-based restricted share units (TRSUs) awarded pursuant"

2021 Long Term Incentive Plan financial

"awarded pursuant to the Issuer's 2021 Long Term Incentive Plan"

economic equivalent of one share of Common Stock financial

"Each TRSU is the economic equivalent of one share of Common Stock"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did AVNS executive Sigfrido Delgado receive in this Form 4/A?

Sigfrido Delgado received 37,520 employee stock options at a $13.69 exercise price and 15,886 time-based restricted share units. These awards are part of Avanos Medical’s 2021 Long Term Incentive Plan and represent compensation rather than open-market buying activity.

How do the new awards affect Sigfrido Delgado’s AVNS holdings?

After the awards, Sigfrido Delgado holds 59,434 stock options and 60,005 shares of Avanos Medical common stock directly. The filing shows these grants increase his equity-based compensation exposure but do not reflect any stock sales or market purchases.

What are the vesting terms of Sigfrido Delgado’s AVNS restricted share units?

The time-based restricted share units vest over three years: one-third on March 13, 2027, one-third on March 13, 2028, and one-third on March 13, 2029. Each unit is economically equivalent to one share of Avanos Medical common stock upon vesting.

What is the exercise price and expiration date of Delgado’s new AVNS stock options?

The newly granted employee stock options have a $13.69 per share exercise price and expire on March 13, 2036. This gives Delgado a long-dated right to buy Avanos Medical common stock at that fixed price if future conditions make exercising attractive.

Were Sigfrido Delgado’s AVNS transactions open-market buys or compensation grants?

The transactions are compensation grants, not open-market buys. Both the stock options and restricted share units were awarded at a reported price of $0.00 per share under Avanos Medical’s long-term incentive plan, reflecting equity-based pay rather than discretionary market purchases.

Which Avanos Medical incentive plan governs these awards to Sigfrido Delgado?

The restricted share units were granted under Avanos Medical’s 2021 Long Term Incentive Plan, as amended. This plan allows the company to issue equity-based awards like options and restricted units to executives, aligning part of their compensation with shareholder interests over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 03:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Delgado Sigfrido

(Last) (First) (Middle)

5405 WINDWARD PKWY

(Street)

ALPHARETTA GEORGIA 30004-4667

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/01/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		15,886(1)	A	$0	60,005	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.69	03/13/2026		A		37,520		(2)	03/13/2036	Common Stock	37,520	$0	59,434	D

Explanation of Responses:

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.

2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Remarks:

This Form 4/A is being filed to correct a Form 4/A filed on April 1, 2026 that erroneously added to the number of stock options issued to the Reporting Person on March 13, 2026 pursuant to the Issuer's 2021 Long-Term Incentive Plan, as amended. The number of stock options originally reported in the Form 4 filed on March 17, 2026 was correct.

	/s/ John Hurley, as attorney-in-fact for Sigfrido Delgado	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)